Attovia Therapeutics has filed for an IPO to secure funding for assets, including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.
Source: FierceBiotech
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.